Rigin (Palmitoyl Tetrapeptide-7)

Rigin reduces IL-6 secretion by keratinocytes after UVB exposure, helping reduce chronic low-grade inflammation in aging skin (inflammaging). It is a key component of the Matrixyl 3000 complex alongside Palmitoyl Oligopeptide.

Category: Cosmetic. Evidence rating: D (animal/preclinical only).

Clinical status: Cosmetic ingredient

Inhibits IL-6 secretion from UVB-exposed keratinocytes. Modulates complement system activity and dampens chronic inflammatory signaling associated with skin aging.

Safety considerations: Well-tolerated topically.

Reviewed by the PeptideAtlas Editorial Team.

Rigin (Palmitoyl Tetrapeptide-7) — measured properties

Production methodsynthetic
Anti-doping statusnot-listed

Related peptides: Decapeptide-12, Melanostatin-DM (Nonapeptide-2), Nonapeptide-1.

Frequently asked questions

What is RIGIN?

Rigin (Palmitoyl Tetrapeptide-7) is a lipopeptide that reduces inflammation-driven skin aging by inhibiting IL-6 secretion, commonly paired with Pal-GHK in anti-aging formulations.

What are the research benefits of RIGIN?

RIGIN has been studied for: Anti-inflammatory, Inflammaging reduction, IL-6 suppression, Skin aging prevention. Cosmetic lipopeptide; key ingredient in Matrixyl 3000 alongside Pal-GHK.

How does RIGIN work?

Suppresses interleukin-6 (IL-6) and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing chronic low-grade inflammation (inflammaging) in skin tissue.